Floatz logo

Lonafarnib

Hepatitis D

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Small moleculePhase 2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
40/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Hepatitis D cohort.

Asset / SponsorPhaseRating
RITONAVIR
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 2B
Lamivudine
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 2B
Pegylated Interferon Alpha2A
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 2B
Peg-Interferon Lambda
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 2B
Bulevirtide
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
D
Rep 2139-Mg
D
TENOFOVIR DISOPROXIL FUMARATE
D

Same molecule, other indications

Lonafarnib is also rated in:

Hutchinson-Gilford progeria syndromeDormant
B
Indicative ·
58 / 100
View asset →
metastatic neoplasmDormant
B
Indicative ·
57 / 100
View asset →
renal pelvis/ureter urothelial carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →